What is Indigo BioAutomation?
Founded in 2006 as Indigo Biosystems within the Eli Lilly research ecosystem, Indigo BioAutomation specializes in transforming laboratory workflows through a data-centric methodology. Unlike traditional document-based systems, the company provides advanced software solutions—most notably its flagship platform, ASCENT—that enable researchers to interact directly with raw data layers. By integrating expertise in mass spectrometry, big data analytics, and algorithmic process automation, Indigo facilitates what it terms factory science. This approach is critical for clinical, pharmaceutical, and biotechnology laboratories that require rapid, high-fidelity decision-making capabilities to maintain competitive operational standards in increasingly complex research landscapes.
The company's market position is defined by its ability to bridge the gap between raw scientific output and actionable management insights. By automating data integration and analysis, Indigo BioAutomation addresses the persistent bottleneck of manual data handling, thereby enhancing both the throughput and the quality of scientific discovery. Their focus on high-throughput environments positions them as a vital partner for organizations seeking to modernize their laboratory infrastructure.
How much funding has Indigo BioAutomation raised?
Indigo BioAutomation has raised a total of $10.7M across 3 funding rounds:
Private Equity
$1.8M
Series B
$8.5M
Debt
$350K
Private Equity (2010): $1.8M, investors not publicly disclosed
Series B (2014): $8.5M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Key Investors in Indigo BioAutomation
PPP
Public-Private Partnership
Undisclosed Investor
An institutional backer participating in private equity rounds to support long-term enterprise scaling.
Undisclosed Investor
A strategic partner providing capital for Series B expansion and technological development.
What's next for Indigo BioAutomation?
With the recent infusion of $350K, Indigo BioAutomation is well-positioned to accelerate the deployment of its ASCENT platform across broader life science markets. The strategic focus will likely shift toward deepening the integration of advanced machine learning algorithms to further refine the factory science model. As the industry moves toward more automated, data-driven research paradigms, Indigo's ability to scale its software architecture will be paramount. Future growth will likely involve expanding its footprint in global clinical laboratories, where the demand for automated data integrity and regulatory compliance remains at an all-time high. The company's history of sustained investment suggests a long-term commitment to maintaining its status as a leading provider of laboratory operational software.
See full Indigo BioAutomation company page
